Cargando…

Traitement de la neuromyélite optique de Devic durant de la grossesse

Neuromyelitis optica (Devic’s disease) is an inflammatory demyelinating disease of the central nervous system that mainly affects spinal cord, optic nerve and brain regions with high aquaporin 4 antigen expression. This is a severe autoimmune disease caused by autoantibodies directed against aquapor...

Descripción completa

Detalles Bibliográficos
Autores principales: Daouda, Moussa Toudou, Obenda, Norlin Samuel, Assadeck, Hamid, Camara, Diankanagbe, Djibo, Fatimata Hassane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The African Field Epidemiology Network 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075488/
https://www.ncbi.nlm.nih.gov/pubmed/27800085
http://dx.doi.org/10.11604/pamj.2016.24.230.9167
_version_ 1782461875686998016
author Daouda, Moussa Toudou
Obenda, Norlin Samuel
Assadeck, Hamid
Camara, Diankanagbe
Djibo, Fatimata Hassane
author_facet Daouda, Moussa Toudou
Obenda, Norlin Samuel
Assadeck, Hamid
Camara, Diankanagbe
Djibo, Fatimata Hassane
author_sort Daouda, Moussa Toudou
collection PubMed
description Neuromyelitis optica (Devic’s disease) is an inflammatory demyelinating disease of the central nervous system that mainly affects spinal cord, optic nerve and brain regions with high aquaporin 4 antigen expression. This is a severe autoimmune disease caused by autoantibodies directed against aquaporin 4 and associated with high morbidity and mortality. Unlike other inflammatory conditions such as multiple sclerosis or rheumatoid polyarthritis, pregnancy does not seem to influence the activity of neuromyelitis optica, hence the need for a thorough treatment during pregnancy. Corticosteroid therapy is the treatment of choice for neuromyelitis optica during pregnancy. Other treatments may also be used including rituximab, some immunosuppressive agents and immunoglobulins. Immunosuppressive treatment or rituximab is recommended when the long-term corticosteroid treatment is contraindicated, in case of inefficiency or if side effects are intolerable. Immunoglobulins are administered to patients with serious outbreaks of neuromyelitis optica which do not respond to bolus methylprednisolone. Immunoglobulins alone can also be continued at a dose of 0.4 g/kg/day for 6-8 weeks until delivery. Plasmapheresis is also a good alternative to bolus methylprednisolone when outbreaks are extremely severe.
format Online
Article
Text
id pubmed-5075488
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher The African Field Epidemiology Network
record_format MEDLINE/PubMed
spelling pubmed-50754882016-10-31 Traitement de la neuromyélite optique de Devic durant de la grossesse Daouda, Moussa Toudou Obenda, Norlin Samuel Assadeck, Hamid Camara, Diankanagbe Djibo, Fatimata Hassane Pan Afr Med J Review Neuromyelitis optica (Devic’s disease) is an inflammatory demyelinating disease of the central nervous system that mainly affects spinal cord, optic nerve and brain regions with high aquaporin 4 antigen expression. This is a severe autoimmune disease caused by autoantibodies directed against aquaporin 4 and associated with high morbidity and mortality. Unlike other inflammatory conditions such as multiple sclerosis or rheumatoid polyarthritis, pregnancy does not seem to influence the activity of neuromyelitis optica, hence the need for a thorough treatment during pregnancy. Corticosteroid therapy is the treatment of choice for neuromyelitis optica during pregnancy. Other treatments may also be used including rituximab, some immunosuppressive agents and immunoglobulins. Immunosuppressive treatment or rituximab is recommended when the long-term corticosteroid treatment is contraindicated, in case of inefficiency or if side effects are intolerable. Immunoglobulins are administered to patients with serious outbreaks of neuromyelitis optica which do not respond to bolus methylprednisolone. Immunoglobulins alone can also be continued at a dose of 0.4 g/kg/day for 6-8 weeks until delivery. Plasmapheresis is also a good alternative to bolus methylprednisolone when outbreaks are extremely severe. The African Field Epidemiology Network 2016-07-13 /pmc/articles/PMC5075488/ /pubmed/27800085 http://dx.doi.org/10.11604/pamj.2016.24.230.9167 Text en © Moussa Toudou Daouda et al. http://creativecommons.org/licenses/by/2.0/ The Pan African Medical Journal - ISSN 1937-8688. This is an Open Access article distributed under the terms of the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Daouda, Moussa Toudou
Obenda, Norlin Samuel
Assadeck, Hamid
Camara, Diankanagbe
Djibo, Fatimata Hassane
Traitement de la neuromyélite optique de Devic durant de la grossesse
title Traitement de la neuromyélite optique de Devic durant de la grossesse
title_full Traitement de la neuromyélite optique de Devic durant de la grossesse
title_fullStr Traitement de la neuromyélite optique de Devic durant de la grossesse
title_full_unstemmed Traitement de la neuromyélite optique de Devic durant de la grossesse
title_short Traitement de la neuromyélite optique de Devic durant de la grossesse
title_sort traitement de la neuromyélite optique de devic durant de la grossesse
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075488/
https://www.ncbi.nlm.nih.gov/pubmed/27800085
http://dx.doi.org/10.11604/pamj.2016.24.230.9167
work_keys_str_mv AT daoudamoussatoudou traitementdelaneuromyeliteoptiquededevicdurantdelagrossesse
AT obendanorlinsamuel traitementdelaneuromyeliteoptiquededevicdurantdelagrossesse
AT assadeckhamid traitementdelaneuromyeliteoptiquededevicdurantdelagrossesse
AT camaradiankanagbe traitementdelaneuromyeliteoptiquededevicdurantdelagrossesse
AT djibofatimatahassane traitementdelaneuromyeliteoptiquededevicdurantdelagrossesse